{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:33:03Z","timestamp":1777948383131,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50-CA100632"],"award-info":[{"award-number":["P50-CA100632"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.beha.2025.101611","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:13:12Z","timestamp":1741752792000},"page":"101611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-GM-CSF autoantibodies in myeloid leukemias"],"prefix":"10.1016","volume":"38","author":[{"given":"Anna","family":"Sergeeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wingchi K.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"St John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey J.","family":"Molldrem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/icb.1966.28","article-title":"The growth of mouse bone marrow cells in vitro","volume":"44","author":"Bradley","year":"1966","journal-title":"Aust J Exp Biol Med Sci"},{"key":"10.1016\/j.beha.2025.101611_bib2","first-page":"27","article-title":"The discovery, development and clinical applications of granulocyte colony-stimulating factor","volume":"109","author":"Dale","year":"1998","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"7","key":"10.1016\/j.beha.2025.101611_bib3","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/jimmunol\/198.7.2522","article-title":"Pillars article: molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature. 1984. 309: 763-767","volume":"198","author":"Gough","year":"2017","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.beha.2025.101611_bib4","doi-asserted-by":"crossref","first-page":"9238","DOI":"10.1016\/S0021-9258(19)76530-2","article-title":"Resolution and purification of three distinct factors produced by Krebs ascites cells which have differentiation-inducing activity on murine myeloid leukemic cell lines","volume":"263","author":"Hilton","year":"1988","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.beha.2025.101611_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-03-079681","article-title":"Hematopoietic cytokines","volume":"111","author":"Metcalf","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101611_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/annonc\/mdl158","article-title":"Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients","volume":"18","author":"Parmiani","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101611_bib7","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cell.2008.05.053","article-title":"The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation","volume":"134","author":"Hansen","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.beha.2025.101611_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a double-edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2025.101611_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/stem.5530070104","article-title":"Role of colony-stimulating factors in the biology of acute myelogenous leukemia","volume":"7","author":"Oster","year":"1989","journal-title":"Int J Cell Clon"},{"issue":"1\u20132","key":"10.1016\/j.beha.2025.101611_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/10428199909093728","article-title":"Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells","volume":"33","author":"Drexler","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2025.101611_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/08977194.2011.649919","article-title":"The GM-CSF receptor family: mechanism of activation and implications for disease","volume":"30","author":"Hercus","year":"2012","journal-title":"Growth Factors"},{"issue":"10","key":"10.1016\/j.beha.2025.101611_bib13","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bmt.2013.57","article-title":"First use of myeloid colony-stimulating factors in humans","volume":"48","author":"Gale","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101611_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.706186","article-title":"Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time?","volume":"12","author":"Lazarus","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.beha.2025.101611_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of Pegfilgrastim","volume":"50","author":"Yang","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.beha.2025.101611_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJM198809083191001","article-title":"Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression","volume":"319","author":"Antman","year":"1988","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2025.101611_bib17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1445-5994.1991.tb01371.x","article-title":"GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and lymphocytes","volume":"21","author":"Atkinson","year":"1991","journal-title":"Aust N Z J Med"},{"issue":"11","key":"10.1016\/j.beha.2025.101611_bib18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/14712598.2022.2143261","article-title":"Sargramostim in acute radiation syndrome","volume":"22","author":"Lazarus","year":"2022","journal-title":"Expet Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.beha.2025.101611_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJM198709033171003","article-title":"Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome","volume":"317","author":"Groopman","year":"1987","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.1991.tb08573.x","article-title":"Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes","volume":"77","author":"Estey","year":"1991","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.beha.2025.101611_bib21","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJM198712173172501","article-title":"Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes","volume":"317","author":"Vadhan-Raj","year":"1987","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood.V73.3.694.694","article-title":"Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor","volume":"73","author":"Champlin","year":"1989","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101611_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1359-6101(01)00034-X","article-title":"GM-CSF-based cellular vaccines: a review of the clinical experience","volume":"13","author":"Borrello","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8","key":"10.1016\/j.beha.2025.101611_bib24","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","article-title":"Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity","volume":"90","author":"Dranoff","year":"1993","journal-title":"Proc Natl Acad Sci U.S.A"},{"issue":"5","key":"10.1016\/j.beha.2025.101611_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.coi.2006.07.005","article-title":"Immunotherapeutic peptide vaccination with leukemia-associated antigens","volume":"18","author":"Rusakiewicz","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.beha.2025.101611_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1600-065X.2002.18813.x","article-title":"GM-CSF-based cancer vaccines","volume":"188","author":"Dranoff","year":"2002","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/leu.2016.254","article-title":"PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies","volume":"31","author":"Qazilbash","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2025.101611_bib28","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","article-title":"Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients","volume":"25","author":"Mittendorf","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.beha.2025.101611_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/1940-6207.CAPR-22-0388","article-title":"Phase II trial of nelipepimut-S peptide vaccine in women with ductal carcinoma in situ","volume":"16","author":"O'Shea","year":"2023","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"10.1016\/j.beha.2025.101611_bib30","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-13-2817","article-title":"Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3\/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells","volume":"20","author":"Rapoport","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.beha.2025.101611_bib31","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-16-3016","article-title":"Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697)","volume":"23","author":"Butterfield","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7745","key":"10.1016\/j.beha.2025.101611_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-0959-z","article-title":"Publisher Correction: actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"566","author":"Hilf","year":"2019","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.beha.2025.101611_bib33","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1089\/hum.1998.9.13-1951","article-title":"A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma","volume":"9","author":"Jaffee","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib34","first-page":"194","article-title":"Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials","volume":"4","author":"Jaffee","year":"1998","journal-title":"Cancer J Sci Am"},{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/00005537-200303000-00029","article-title":"Genetically engineered tumor cell vaccine in a head and neck cancer model","volume":"113","author":"Couch","year":"2003","journal-title":"Laryngoscope"},{"issue":"19","key":"10.1016\/j.beha.2025.101611_bib36","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.beha.2025.101611_bib37","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/bloodadvances.2021006255","article-title":"GM-CSF secreting leukemia cell vaccination for MDS\/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial","volume":"6","author":"Ho","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.beha.2025.101611_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.leu.2405104","article-title":"High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease","volume":"22","author":"Sergeeva","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2025.101611_bib39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10875-024-01775-w","article-title":"The pathogenic role of anti-granulocyte-macrophage colony-stimulating factor autoantibodies in the nocardiosis with the central nervous system involvement","volume":"44","author":"Lo","year":"2024","journal-title":"J Clin Immunol"},{"issue":"1\u20132","key":"10.1016\/j.beha.2025.101611_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2013.11.011","article-title":"Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis","volume":"402","author":"Uchida","year":"2014","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.beha.2025.101611_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10875-016-0364-4","article-title":"Disseminated cryptococcosis due to anti-granulocyte-macrophage colony-stimulating factor autoantibodies in the absence of pulmonary alveolar proteinosis","volume":"37","author":"Kuo","year":"2017","journal-title":"J Clin Immunol"},{"issue":"11","key":"10.1016\/j.beha.2025.101611_bib42","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1182\/blood-2008-05-155689","article-title":"Granulocyte\/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects","volume":"113","author":"Uchida","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101611_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2009-08-241018","article-title":"Are neutralizing anti-GM-CSF autoantibodies present in all healthy persons?","volume":"115","author":"Meager","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101611_bib44","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/ncomms8375","article-title":"Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis","volume":"6","author":"Piccoli","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.beha.2025.101611_bib45","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.4049\/jimmunol.1202526","article-title":"Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis","volume":"190","author":"Rosen","year":"2013","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.beha.2025.101611_bib46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1084\/jem.190.6.875","article-title":"Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte\/macrophage colony-stimulating factor","volume":"190","author":"Kitamura","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2025.101611_bib47","article-title":"Pulmonary alveolar proteinosis","author":"Carrington","year":"20241","journal-title":"StatPearls. Treasure Island (FL)"},{"issue":"2","key":"10.1016\/j.beha.2025.101611_bib48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2217\/bmm-2017-0362","article-title":"Clinical significance of serum anti-GM-CSF autoantibody levels in autoimmune pulmonary alveolar proteinosis","volume":"12","author":"Nishimura","year":"2018","journal-title":"Biomarkers Med"},{"issue":"5","key":"10.1016\/j.beha.2025.101611_bib49","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00725-2024","article-title":"European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis","volume":"64","author":"McCarthy","year":"2024","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.beha.2025.101611_bib50","first-page":"L709","article-title":"Surfactant metabolic consequences of overexpression of GM-CSF in the epithelium of GM-CSF-deficient mice","volume":"273","author":"Ikegami","year":"1997","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.beha.2025.101611_bib51","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00500-2023","article-title":"Altered macrophage phenotypes in a case of autoimmune pulmonary alveolar proteinosis","volume":"9","author":"Hata","year":"2023","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib52","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccm.2016.04.006","article-title":"Pulmonary alveolar proteinosis syndrome","volume":"37","author":"Suzuki","year":"2016","journal-title":"Clin Chest Med"},{"issue":"25","key":"10.1016\/j.beha.2025.101611_bib53","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1056\/NEJM199612193352513","article-title":"Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis","volume":"335","author":"Seymour","year":"1996","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2025.101611_bib54","first-page":"1018","article-title":"The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities","volume":"10","author":"Dhagat","year":"2018","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.beha.2025.101611_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.hemonc.2014.09.003","article-title":"Secondary pulmonary alveolar proteinosis in hematologic malignancies","volume":"7","author":"Chaulagain","year":"2014","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"10.1016\/j.beha.2025.101611_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12890-018-0590-z","article-title":"Secondary pulmonary alveolar proteinosis: a single-center retrospective study (a case series and literature review)","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10.1016\/j.beha.2025.101611_bib57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0145-2126(01)00178-3","article-title":"Pulmonary alveolar proteinosis as a terminal complication in myelodysplastic syndromes: a report of four cases detected on autopsy","volume":"26","author":"Shoji","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2025.101611_bib58","first-page":"1","article-title":"Role of granulocyte-macrophage colony-stimulating factor in acute myeloid leukemia\/myelodysplastic syndromes","volume":"4","author":"Kassem","year":"2018","journal-title":"J Glob Oncol"},{"issue":"5","key":"10.1016\/j.beha.2025.101611_bib59","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.cmi.2024.01.018","article-title":"Anti-GM-CSF autoantibodies predict outcome of cryptococcal meningitis in patients not infected with HIV: a cohort study","volume":"30","author":"Jiang","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.beha.2025.101611_bib60","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10875-023-01451-5","article-title":"Anti-GM-CSF neutralizing autoantibodies in Colombian patients with disseminated cryptococcosis","volume":"43","author":"Arango-Franco","year":"2023","journal-title":"J Clin Immunol"},{"issue":"8","key":"10.1016\/j.beha.2025.101611_bib61","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/MIB.0b013e318281f506","article-title":"Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease","volume":"19","author":"Gathungu","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.beha.2025.101611_bib62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1006\/clim.2000.4999","article-title":"Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation","volume":"99","author":"Ullenhag","year":"2001","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.beha.2025.101611_bib63","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.1996.14.4.1371","article-title":"Use of cytokines in the treatment of acute myelocytic leukemia: a critical review","volume":"14","author":"Geller","year":"1996","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2025.101611_bib64","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2249.1996.11704.x","article-title":"Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy","volume":"104","author":"Wadhwa","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.beha.2025.101611_bib65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2004.09.009","article-title":"Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF)","volume":"29","author":"Rini","year":"2005","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.beha.2025.101611_bib66","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2326-6066.CIR-14-0100","article-title":"Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide","volume":"3","author":"Mitchell","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.beha.2025.101611_bib67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/CEOR.S360741","article-title":"Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with coronavirus disease 19 (COVID-19) from the perspective of national health service england","volume":"14","author":"Kilcoyne","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"issue":"7","key":"10.1016\/j.beha.2025.101611_bib68","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.2019004352","article-title":"Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia","volume":"136","author":"Patnaik","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib69","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/imm.13842","article-title":"Plonmarlimab, a novel anti-GM-CSF blocking antibody, ameliorates disease progression in the pre-clinical model of macrophage activation syndrome","volume":"173","author":"Ding","year":"2024","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.beha.2025.101611_bib70","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.joca.2020.01.012","article-title":"Targeting GM-CSF for collagenase-induced osteoarthritis pain and disease in mice","volume":"28","author":"Lee","year":"2020","journal-title":"Osteoarthr Cartil"},{"issue":"3","key":"10.1016\/j.beha.2025.101611_bib71","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-2600(21)00494-X","article-title":"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial","volume":"10","author":"Temesgen","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"4 Suppl 98","key":"10.1016\/j.beha.2025.101611_bib72","first-page":"39","article-title":"Targeting GM-CSF in rheumatoid arthritis","volume":"34","author":"Avci","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.beha.2025.101611_bib73","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard-2023-224482","article-title":"Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.beha.2025.101611_bib74","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.beha.2025.101611_bib75","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody","volume":"180","author":"Papp","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.beha.2025.101611_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007709","article-title":"Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma","volume":"6","author":"Molfino","year":"2016","journal-title":"BMJ Open"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:28:58Z","timestamp":1777793338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1521692625000167"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101611","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-GM-CSF autoantibodies in myeloid leukemias","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101611"}}